CONVENIA® (cefovecin sodium) is an ideal treatment for skin infections caused by susceptible organisms. Why? The unique pharmacokinetic profile of CONVENIA makes it optimal for a time-dependent antibiotic,1,2 providing:
Eighty-six percent first-time resolution3 of superficial pyoderma.
Rapid onset of action.
Excellent efficacy.
The science behind CONVENIA
Pharmacokinetics1,2
CONVENIA has a unique pharmacokinetic profile. The aqueous, non-depot injection:
Is rapidly and completely absorbed into the bloodstream.
Quickly reaches peak plasma levels:
Dogs average 6.2 hours.
Cats average 2.0 hours.
Is highly protein-bound:10
Dog plasma 98.5%.
Cat plasma 99%.
Does not undergo hepatic metabolism; majority of ose is excreted unchanged in urine.
CONVENIA has a distinctively long half-life:
Concentrations above the MIC at the site of infection in as soon as 2 hours and maintained for up to 14 days.
Dogs 5.5-day average.*
Cats 6.9-day average.*
How CONVENIA compares with other cephalosporins:
The question of subtherapeutic concentrations & resistance
All antibiotics have subtherapeutic concentrations during the dosing interval.
Poor compliance with oral medications can prolong these subtherapeutic concentrations.
Bacteria are either sensitive or resistant to an antibiotic.
Following treatment, all susceptible bacteria are killed, selecting for the resistant bacteria.
An antibiotic is not expected to have any effect on resistant organisms. This is true for all antibiotics.
With regard to antimicrobial resistance, the veterinary literature regarding Staphylococcus pseudintermedius and E. coli does not indicate that any antibiotic or class of antibiotics is more likely to result in resistance. It is the use of antibiotics in general.17-31
